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Available online 1 July 2016Purpose: The purpose of this study was to evaluate the efﬁcacy and safety of adjunctive retigabine/ezogabine
(RTG/EZG) therapy in Asian adults with partial-onset seizures.
Methods: A Phase III, randomized, double-blind, placebo-controlled, parallel-group study was conducted at
26 centers in Asia. Eligible patients were randomized in a 1:1:1 ratio to receive RTG/EZG 600 mg/day (200 mg
3 times daily), RTG/EZG 900 mg/day (300 mg 3 times daily), or placebo. The study consisted of an 8-week
screening/baseline phase, followed by a 16-week treatment phase (4-week titration phase and 12-week
maintenance phase).
Results: The studywas terminated early because of emerging safety information onRTG/EZG (i.e., retinal pigmen-
tation and skin/mucosal discoloration) from long-term trials. Of 132 patients screened and 76 randomized,
75 (placebo, n = 25; RTG/EZG 600 mg/day, n = 26; RTG/EZG 900 mg/day, n = 24) received at least 1 dose of
the study drug andwere included in the safety and intent-to-treat populations. The responder rate (≥50% reduc-
tion in 28-day total partial-onset seizure frequency) was 31% with RTG/EZG 600 mg/day and 17% with RTG/EZG
900 mg/day versus 0% with placebo. Median percent change from baseline in 28-day total partial-onset seizure
frequency during the maintenance phase was −33.90% and −22.46% with RTG/EZG 600 and 900 mg/day,
respectively, versus−22.21% with placebo. No new safety concerns were identiﬁed.
Conclusions: Insufﬁcient data were obtained to permit deﬁnitive conclusions. However, the results appear to be
broadly in line with those from previous studies that included primarily Caucasian patients.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Classiﬁcation:
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Retigabine1. Introduction
Retigabine (RTG; international nonproprietary name)/ezogabine
(EZG; United States adopted name) is an antiepileptic drug (AED) that
has recently been approved for the adjunctive treatment of partial-
onset seizures in adults who have responded inadequately to other
treatments and for whom the beneﬁts outweigh the risk of retinal
abnormalities [1].loor, Menara Selatan, University
aysia. Tel.: +60 14 7214303;
rinder.k.lotay@gsk.com
kwan@unimelb.edu.au
ation: PAREXEL International,
. This is an open access article underRetigabine/ezogabine has a unique primary pharmacologic action
among the current AEDs, mediated through facilitation of the opening
of speciﬁc neuronal voltage-gated potassium channels (potassium central
nervous systemQ [KCNQ] channels),which causes a hyperpolarizing shift
in the potassium current and reduces the excitability of the neuronal cell
[2]. In addition to its primary activity at KCNQ channels, RTG/EZG aug-
ments γ-aminobutyric acid-mediated inhibitory currents, which may
also confer a stabilizing effect on neuronal excitability [3].
Retigabine/ezogabine was shown to be efﬁcacious as adjunctive
therapy in three double-blind, randomized, placebo-controlled studies
in adults with refractory partial-onset seizures [4–6]. Based on the
results from these pivotal studies, RTG/EZG was initially approved in
2011 in the USA and the European Union for the adjunctive treatment
of partial-onset seizures in adults.
Ethnic differences in host and environmental factors may adversely
affect safety and efﬁcacy of medications, including AEDs. For instance,
the incidence of carbamazepine-induced Stevens–Johnson syndromethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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bly because the former have ahigher carrier rate ofHLA-B*15:02,which is
strongly predictive of this adverse drug reaction [7]. In the trials onwhich
EU and US approvals of RTG/EZG were based, only 10 Asian patients, of
whom 5 received RTG/EZG, were included in the 1240 patients who re-
ceived study medication [4–6]. The present study was initiated in 2012
to evaluate the efﬁcacy, safety, and tolerability of RTG/EZG in adult
Asian patients with drug-resistant partial-onset seizures. However, with
the emergence of data concerning the risk of retinal pigmentation and
possible visual impairment associated with RTG/EZG treatment, the indi-
cated patient population was revised in May 2013 such that patients
could be treated with RTG/EZG only when other appropriate drug
combinations had proved inadequate or intolerable. As a result of this
development, the enrolled patients were unblinded, and the study was
terminated early. Here, we report the descriptive efﬁcacy results and
safety outcomes for the intent-to-treat (ITT) population.
2. Methods
2.1. Study design
This was a randomized, double-blind, placebo-controlled, parallel-
group, multicenter, Phase III study, NCT01777139, to compare the
efﬁcacy, safety, and tolerability of RTG/EZG at doses of 600 mg/day
and 900 mg/day versus placebo as adjunctive therapy in adult Asian
patients with drug-resistant partial-onset seizures. The study was con-
ducted at 26 centers in Hong Kong, the Republic of Korea, Malaysia,
Singapore, Taiwan, and Thailand. Of these, 19 centers enrolled patients;
the other centers screened patients who did not enroll in the study. The
ﬁrst patient was screened on August 29, 2012, and the ﬁrst patient was
randomized to treatment on October 25, 2012. The studywas terminated
early, and the date of the last patient's last visit was December 23, 2013.
Eligible patients were randomized in a 1:1:1 ratio to receive RTG/
EZG 600 mg/day (200 mg 3 times daily [TID]), RTG/EZG 900 mg/day
(300 mg TID), or placebo in a double-blind fashion. The study consisted
of an 8-week screening/baseline phase, a 16-week treatment phase
(consisting of titration and maintenance phases), and a 4-week transi-
tion or taper/follow-up phase. Randomization followed the screening/
baseline phase (Fig. 1). At the end of themaintenance phase, eligible patientsFig. 1. Studydesign. *Patientswho successfully completed themaintenance phase andwere eligi
16. †Patients who were not eligible to enter the OLE study or who withdrew from the study duwere given the opportunity to enroll in an open-label extension (OLE) study
(Study RTG114873).
After due consideration of new safety information, the study was
terminated. Ongoing patients who were randomized to placebo at the
time of study closure were to be withdrawn from the study at the
next visit or, if in transition to the OLE study, withdrawn as soon as
possible after being tapered off the study drug. Ongoing patients
randomized to RTG/EZG were to undergo a beneﬁt–risk assessment.
Patients with a favorable beneﬁt–risk assessment were to continue
treatment and would be permitted to continue into the OLE study.
Otherwise, they were to be tapered from the study medication.
2.1.1. Ethics
Study protocols, consent forms, and other relevant informationwere
reviewed and approved by the relevant Institutional Review Board/
Institutional Ethics Committee. The study was conducted in accordance
with the International Conference on Harmonisation of Technical Re-
quirements for Registration of Pharmaceuticals for Human Use, Good
Clinical Practice, and all applicable local regulatory requirements, as
well as with the guiding principles of the Declaration of Helsinki.
Written informed consent was obtained from all patients prior to
participation in the study.
2.2. Study population
Eligible patients were Asianmen andwomen at least 18 years of age
who had a conﬁrmed diagnosis of epilepsy with partial-onset seizures
with or without secondary generalization for at least 2 years and who
were currently taking 1, 2, or 3 AEDs with or without vagus nerve stim-
ulator (VNS). Patients were eligible if they were having partial-onset
seizures despite prior treatment with at least 2 approved AEDs, either
alone or together, at adequate doses for a sufﬁcient length of time, in
the opinion of the investigator. Additionally, patients were required to
have a documented 28-day partial-onset seizure frequency rate of at
least 4 seizures over the 8 weeks preceding the screening visit and
could not have been seizure-free for 21 ormore consecutive days. In pa-
tients with simple partial seizures, only seizures with motor signs were
counted towards meeting the inclusion criteria.ble to enter the open-label extension (OLE) studywere to enter the titration phase atWeek
ring the maintenance phase were to enter the taper/follow-up phase.
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tive days; presence of any of the prespeciﬁed disqualifying conditions;
previous exposure to retigabine; or treatment with felbamate or
vigabatrin ≤6 months prior to screening.
Other eligibility criteria, detailed key exclusion criteria, and random-
ization criteria are described in the Supplemental Materials.
The ITT population was the primary efﬁcacy population and
included all patients in the safety population who had baseline seizure
data and ≥1 postbaseline seizure record (whether or not they had a
seizure) between the start of the titration phase and the end of the
maintenance phase. The safety population was the primary population
for evaluation of safety parameters and included all patients who
received ≥1 dose of study medication.2.3. Efﬁcacy assessments
Primary and secondary efﬁcacy assessments were based on seizure
frequency, which was recorded by patients or their primary caregivers
in a daily calendar by seizure type, duration of episodes of innumerable
seizure activity, and occurrence of status epilepticus as recorded in the
calendar during each study phase.
The primary efﬁcacy endpoint was the proportion of responders,
deﬁned as patients with ≥50% reduction in 28-day total partial-onset
seizure frequency, from the baseline phase to the maintenance phase,
in patients randomized to RTG/EZG 900 mg/day compared with those
randomized to placebo. Secondary efﬁcacy endpoints included the pro-
portion of responders in the RTG/EZG 600-mg/day group compared
with the placebo group, the proportion of responders in the entire treat-
ment phase, the percent change from baseline in 28-day total partial-
onset seizure frequency and the proportion of patients who were
seizure-free during the maintenance and treatment phases, and the in-
cidence of new seizure types. Patientswhodropped out during the titra-
tion phase were classiﬁed as nonresponders during the maintenance
phase. For patients who dropped out during the titration phase, percent
change from baseline in 28-day total partial-onset seizure frequency
during the maintenance phase was calculated based on titration phase
data. For all others, only maintenance phase data were used to calculate
percent change from baseline.2.4. Pharmacokinetic (PK) assessments
The PK endpoint was systemic exposure to RTG/EZG. Blood samples
were collected during the titration and maintenance phases at every
scheduled clinic visit together with details of the last dose of investiga-
tional product and time of sample collection.2.5. Safety assessments
Safety and tolerability endpoints included the following: incidence
and severity of adverse events (AEs); proportion of patients with AEs
leading to discontinuation; changes from baseline in vital signmeasure-
ments, body weight, electrocardiogram, hematology, chemistry, and
urinalysis parameters; changes from baseline in American Urological
Association Symptom Index and postvoid residual bladder ultrasound
volumes; and assessment of suicidality via use of the summary of the
Columbia-Suicide Severity Rating Scale.
After reports of retinal pigmentation and skin/mucosal discoloration
in patients taking RTG/EZG in long-term studies, comprehensive
ophthalmic and dermatologic examinations were performed to assess
retinal and nonretinal pigmentary abnormalities, pigmentation of
nonretinal ocular tissues, and changes in visual acuity and the confronta-
tion visual ﬁeld from the initial examination. Details of these comprehen-
sive eye and dermatologic examinations are provided in Supplementary
Information.2.6. Statistical analyses
Sample size calculation was based on detecting the difference in the
responder rate between RTG/EZG 900 mg/day and placebo. On the
assumption that the allocation ratio of RTG/EZG 900mg/day and place-
bo is 1:1, at least 112 patients per treatment group in the ITT population
were required to detect a difference of 20% in the responder rate
between RTG/EZG 900 mg/day and placebo with 90% power. Sample
size was based on an assumed placebo responder rate of 17% and an
RTG/EZG900-mg/day responder rate of 37% [5,6]. A 2-sided signiﬁcance
level of 0.05 was used in this study.
The randomization scheme for the study was 1:1:1 for the 3 treat-
ment groups, which would provide a total of approximately
336 evaluable patients. Assuming that 5% of randomized patients
would not have at least 1 postbaseline seizure record, approximately
354 patients were to be randomized to achieve a minimum of 112 pa-
tients per treatment group in the ITT population.
Owing to the early termination of the study, abbreviated statistical
outputs were generated, which included listings and descriptive sum-
maries of available collected data. No hypothesis testingwas performed.
3. Results
3.1. Study population
A total of 132 patients were screened, of whom 12 were rescreened
(N=144; Fig. 2). Of the total, 28 patients did notmeet eligibility criteria
and a further 40 entering the baseline phase were not randomized. A
total of 76 patients were randomized, of whom 75 (placebo, n = 25;
RTG/EZG 600 mg/day, n = 26; RTG/EZG 900 mg/day, n = 24) received
at least 1 dose of study drug and were included in the safety and ITT
populations. Twenty patients in the placebo group, 20 in the RTG/EZG
600-mg/day group, and 12 in the RTG/EZG 900-mg/day group complet-
ed the treatment phase. Of the 75 patients in the safety population, 35
completed the study (13 in the placebo group, 14 in the RTG/EZG 600-
mg/day group, and 8 in the RTG/EZG 900-mg/day group), and 40 pa-
tients withdrew from the study (12 in the placebo group, 12 in the
RTG/EZG 600-mg/day group, and 16 in the RTG/EZG 900-mg/day
group). Two patients in the placebo group, 3 in the RTG/EZG 600-mg/
day group, and 6 in the RTG/EZG 900-mg/day group withdrew during
the titration phase. A greater proportion of patients discontinued in
the RTG/EZG 900-mg/day group compared with those in the placebo
and RTG/EZG 600-mg/day groups. The primary reason for discontinua-
tion was an AE. After the decision to terminate the study, treatment
blind was broken for 7 patients (3 in the placebo group, 3 in the RTG/
EZG 600-mg/day group, and 1 in the 900-mg/day group).
Demographic and baseline characteristicswere well balanced across
treatment groups (Table 1). Similar percentages of patients had a history
of secondarily generalized seizures in the placebo (64%), RTG/EZG 600-
mg/day (69%), and RTG/EZG 900-mg/day (63%) groups. Across all treat-
ment groups, more patients received 3 background AEDs at baseline,
the largest proportion of whom were in the RTG/EZG 900-mg/day
group (75%). One patient in the RTG/EZG 900-mg/day group had im-
plantedVNS. BackgroundAEDs during the treatment phasewere general-
ly similar across treatment groups. Most patients received more than 1
concomitant AED during the study, commonly carbamazepine, levetirac-
etam, and valproate sodium. A greater proportion of patients in the RTG/
EZG 900-mg/day group (63%) received levetiracetam compared with
those in the placebo (24%) and RTG/EZG 600-mg/day (35%) groups.
3.2. Exposure
Patients in the RTG/EZG 900-mg/day group had a shorter duration of
exposure to the study drug (79.8 days) compared with those in the
placebo (97.7 days) and RTG/EZG 600-mg/day (95.7 days) groups. The
Fig. 2. Patient ﬂow diagram. Note: 2 patients in the placebo group completed the maintenance phase but did not enter the transition phase or taper/follow-up phase. RTG/EZG =
retigabine/ezogabine.
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600-mg/day group and 684.0mg/day in the RTG/EZG 900-mg/day group.
3.3. Efﬁcacy results
As the study was terminated early, summaries of efﬁcacy data
are presented for descriptive purposes only, and results should be
interpreted with caution. No hypothesis testing was performed.
3.3.1. Responder rates
Table 2 shows the proportion of responders for all treatment groups.
During the maintenance phase, the responder rate was 31% in the RTG/
EZG 600-mg/day group and 17% in the RTG/EZG 900-mg/day group,
compared with 0% in the placebo group. Results were similar during
the treatment phase (titration and maintenance).
3.3.2. Seizure frequency and seizure freedom
The median percent change from baseline in 28-day total partial-
onset seizure frequency during the maintenance phase was−33.90% in
the RTG/EZG 600-mg/day group,−22.46% in the RTG/EZG 900-mg/day
group, and−22.21% in the placebo group (Table 3). The correspondingvalues during the entire treatment phase were−36.30% and−26.73%
in the RTG/EZG 600-mg/day and 900-mg/day groups, respectively, com-
pared with−22.55% in the placebo group (Table 3). One patient (4%) in
the RTG/EZG 600-mg/day group was free from seizures during the main-
tenance phase. One patient (4%) in the RTG/EZG 600-mg/day group and
2 patients (8%) in the RTG/EZG 900-mg/day group were free from sei-
zures during the entire treatment phase. No patients in the placebo
group were free from seizures during the study. During the entire treat-
ment phase period, 4 patients experienced a N50% change from baseline
in the 28-day partial seizure rate as follows: one patient in the placebo
group (increase, 54.81%), none in the RTG/EZG 600-mg treatment
group, and 3 patients in the RTG/EZG 900-mg treatment group (increases
of 73.04, 105.94, and 176.36%).
3.4. Seizure type
During the treatment phase, a new seizure type was reported by
2 patients (13%) in the placebo group (simple partial seizures with
motor signs), 1 patient (5%) in the RTG/EZG 600-mg/day group (complex
partial seizures), and 2 patients (10%) in the RTG/EZG 900-mg/day group
(secondarily generalized seizures).
Table 1
Summary of demographic characteristics (safety population).
Placebo
(n = 25)
RTG/EZG
600 mg/day
(n = 26)
RTG/EZG
900 mg/day
(n = 24)
Total
(N = 75)
Age (years)
Median 31.0 36.5 35.0 35.0
Min., Max. 19, 70 19, 56 18, 53 18, 70
Sex, n (%)
Female 10 (40) 10 (38) 10 (42) 30 (40)
Male 15 (60) 16 (62) 14 (58) 45 (60)
Race, n (%)
Asiana 25 (100) 26 (100) 24 (100) 75 (100)
East Asian heritage 15 (60) 16 (62) 17 (71) 48 (64)
Southeast Asian heritage 10 (40) 10 (38) 7 (29) 27 (36)
BMI (kg/m2)
Median 24.1 22.5 23.0 23.1
Min., Max. 17, 33 14, 34 15, 41 14, 41
Partial-onset seizures evolving to
secondarily generalized, n (%)
Yes 16 (64) 18 (69) 15 (63) 49 (65)
No 9 (36) 7 (27) 8 (33) 24 (32)
Unknown 0 1 (4) 1 (4) 2 (3)
Number of AEDs
1 7 (28) 3 (12) 0 10 (13)
2 6 (24) 10 (38) 6 (25) 22 (29)
3 12 (48) 13 (50) 18 (75) 43 (57)
Implanted VNS
Yes 0 0 1 (4) 1 (1)
No 25 (100) 26 (100) 23 (96) 74 (99)
AED: antiepileptic drug; BMI: body mass index; RTG/EZG: retigabine/ezogabine;
SD: standard deviation; VNS: vagus nerve stimulator.
a Patients from Korea, Taiwan, and Hong Kong were classiﬁed as East Asian heritage, pa-
tients from Thailand and Malaysia were classiﬁed as Southeast Asian heritage, and patients
from Singapore self-selected either East Asian or Southeast Asian heritage.
Table 3
Percent change from baseline in 28-day total partial-onset seizure frequency in the main-
tenance and treatment phases (intent-to-treat population).
Placebo
(n = 25)
RTG/EZG
600 mg/day
(n = 26)
RTG/EZG
900 mg/day
(n = 24)
Maintenance phasea
Baseline
Median 11.79 9.66 12.53
Min., Max. 4.4, 518.5 3.9, 59.9 4.5, 154.4
Postbaseline
Median 8.56 7.67 10.07
Min., Max. 3.3, 369.9 0.0, 49.9 0.0, 94.0
Percent change from baseline
Median −22.21 −33.90 −22.46
Min., Max. −48.6, 61.0 −100.0, 16.3 −100.0, 263.6
Treatment phaseb
Baseline
Median 11.79 9.66 12.53
Min., Max. 4.4, 518.5 3.9, 59.9 4.5, 154.4
Postbaseline
Median 9.08 6.75 8.92
Min., Max. 1.3, 347.5 0.0, 46.5 0.0, 73.3
Percent change from baseline
Median −22.55 −36.30 −26.73
Min., Max. −70.5, 54.8 −100.0, 8.2 −100.0, 176.4
ITT: intent to treat; RTG/EZG: retigabine/ezogabine; SD: standard deviation.
a Only patients with baseline and postbaseline seizure measures were included in this
table. Patients who dropped out during the titration phase were calculated on the basis of
titration phase data. For all others, only maintenance phase data were used.
b Only patients with baseline and postbaseline seizure measures were included in this
table. Patients who dropped out during the titration phase were calculated based on titra-
tion phase data. For all others, only maintenance and treatment phase data were used.
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Concentrations of RTG/EZG observed in this study appear consistent
with those observed in theWestern studies and in line with the single-
dose PK study in Taiwanese patients [8]. These results suggest that the
PK proﬁle of RTG/EZG shows no major differences between Asian and
Caucasian patients.3.6. Safety results
A total of 18 patients (72%) in the placebo group, 24 (92%) in the
RTG/EZG 600-mg/day group, and 20 (83%) in the RTG/EZG 900-mg/day
group reported a treatment-emergent AE (TEAE) during the study
(Table 4). Dizziness and somnolence were the most frequently reported
TEAEs in the RTG/EZG groups.Table 2
Proportion of respondersa (intent-to-treat population).
Number (%) of patients
Placebo
(n = 25)
RTG/EZG
600 mg/day
(n = 26)
RTG/EZG
900 mg/day
(n = 24)
Maintenance phaseb
Responders 0 8 (31) 4 (17)
Nonresponders 25 (100) 18 (69) 20 (83)
Treatment phase (titration +maintenance)
Responders 1 (4) 8 (31) 6 (25)
Nonresponders 24 (96) 18 (69) 18 (75)
ITT: intent to treat; RTG/EZG: retigabine/ezogabine.
a A patient was classiﬁed as a responder if there was a ≥50% reduction from baseline in
the 28-day total partial-onset seizure frequency.
b Patients who dropped out during the titration phase were classiﬁed as nonresponders.
For all others, only maintenance phase data were used regardless of time in the phase.Treatment-emergent AEs in the renal and urinary disorder system
organ class were reported by 1 patient (4%) in the placebo group, 3 pa-
tients (12%) in the RTG/EZG 600-mg/day group, and 4 patients (17%) in
the RTG/EZG 900-mg/day group. One patient (4%) in the RTG/EZG
900-mg/day group developed urinary retention that led to withdrawal
from the study. No patients reported suicidal ideation and behavior or
cardiac arrhythmias during the study.
3.6.1. Comprehensive eye examinations
A total of 40 patients, comprising 11 patients in the placebo group,
16 in the RTG/EZG 600-mg/day group, and 13 in the RTG/EZG
900-mg/day group, underwent at least 1 comprehensive eye examina-
tion after commencing treatment. Of these patients, 5/11 (45%) in the
placebo group, 6/16 (38%) in the RTG/EZG 600-mg/day group, and
5/13 (38%) in the RTG/EZG 900-mg/day group had at least 1 abnormal
ﬁnding. Onepatient in the RTG/EZG900-mg/day grouphad abnormal ret-
inal ﬁndings and retinal pigmentary abnormalities, whichwere a result of
previous panretinal photocoagulation by laser. A serious AE (SAE) of
retinal pigmentation was originally reported in the GlaxoSmithKline
safety database (OCEANS) but was later downgraded to a non-AE by
the investigator. However, this was kept as a GlaxoSmithKline serious
event in the OCEANS database. No patients discontinued the study
owing to abnormal retinal pigmentation.
Abnormal pigmentation of nonretinal ocular tissues, including
conjunctiva, corneal epithelium, iris, and lens, was noted equally in
the placebo and treatment groups (5 cases in the placebo group, 6 in
the RTG/EZG 600-mg/day group, and 4 in the RTG/EZG 900-mg/day
group) and was deemed unrelated to the study drug. No patient had a
clinically signiﬁcant decrease in visual acuity from initial examination
or decrease in confrontation visual ﬁeld from initial examination.
3.6.2. Dermatologic examinations
One patient in the RTG/EZG 600-mg/day group and 1 in the RTG/EZG
900-mg/day group reported skin hyperpigmentation TEAEs. One pa-
tient in the RTG/EZG 600-mg/day group reported an AE of melanocytic
Table 4
Overviewof treatment-emergent adverse events and summary ofmost common (N1 patient
in any treatment group) adverse events (safety population).
Number (%) of patients
Placebo
(n = 25)
RTG/EZG
600 mg/day
(n= 26)
RTG/EZG
900 mg/day
(n= 24)
Any TEAE 18 (72) 24 (92) 20 (83)
TEAEs by maximum intensity
Mild 11 (44) 11 (42) 8 (33)
Moderate 5 (20) 11 (42) 9 (38)
Severe 2 (8) 2 (8) 3 (13)
TEAEs related to study treatment
(per investigator judgment)
11 (44) 17 (65) 16 (67)
TEAEs leading to permanent discontinuation
of study treatment or withdrawal of study
5 (20) 8 (31) 10 (42)
TEAE leading to dose reduction 0 0 0
TEAE leading to dose interruption/delay 1 (4) 0 0
Any TESAE 1 (4) 1 (4) 2 (8)
TESAEs related to study treatment 0 1 (4) 0
Fatal TESAEs 1 (4) 0 0
Most common TEAEs (≥1 patient in any
treatment group)
Dizziness 6 (24) 10 (38) 8 (33)
Somnolence 4 (16) 10 (38) 6 (25)
Headache 2 (8) 5 (19) 1 (4)
Tremor 1 (4) 5 (19) 2 (8)
Dyspepsia 0 0 3 (13)
Memory impairment 0 1 (4) 2 (8)
Confusional state 0 2 (8) 1 (4)
Dysuria 0 2 (8) 1 (4)
Diarrhea 1 (4) 0 2 (8)
Ataxia 0 0 2 (8)
Bradyphrenia 0 0 2 (8)
Muscular weakness 0 0 2 (8)
Vision blurred 0 0 2 (8)
Weight increased 0 2 (8) 0
Hypoesthesia 0 2 (8) 0
Upper respiratory tract infection 2 (8) 1 (4) 0
Skin laceration 2 (8) 0 0
Asthenia 2 (8) 0 0
AE: adverse event; RTG/EZG: retigabine/ezogabine; SAE: serious adverse event; TEAE:
treatment-emergent adverse event; TESAE: treatment-emergent serious adverse event.
This table includes the TEAEs in the following phases: titration, maintenance, taper/
follow-up, and transition.
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initiation of the study drug and was considered unrelated to the study
drug by the investigator.3.7. SAEs and other signiﬁcant AEs
One death was reported in the placebo group during the study. The
patient developed pneumonia 127 days after the ﬁrst dose of the
study drug. Treatmentwith the study drugwas stopped, and the patient
waswithdrawn from the study. The patient died 5 days after withdraw-
al, with the cause of death reported as multiple organ failure and
pneumonia; the investigator considered that there was no reasonable
possibility that the pneumonia might have been caused by the study
drug.
Treatment-emergent SAEs (TESAEs) were reported in 1 patient (4%)
in the placebo group (pneumonia), 1 (4%) in the RTG/EZG 600-mg/day
group (dizziness), and 2 (8%) in the RTG/EZG 900-mg/day group (grand
mal convulsion, procedural vomiting, nephrolithiasis). One patient in
the RTG/EZG 600-mg/day group had a TESAE (dizziness) that was
considered by the investigator to be drug related. A total of 3 patients,
including 1 in the placebo group (pneumonia, a fatal SAE), 1 in the
RTG/EZG 600-mg/day group (dizziness), and 1 in the RTG/EZG
900-mg/day group (nephrolithiasis) had TESAEs that led to discontinu-
ation of the study drug.4. Discussion
As the study was terminated prematurely, insufﬁcient data were
available to permit a deﬁnitive conclusion on the efﬁcacy of RTG/EZG
as adjunctive therapy in adult Asian patientswith partial-onset seizures.
The use of a forced titration design was selected to ensure that efﬁcacy
and safety data would be comparable with data reported in the pivotal
trials. Responder rates in the RTG/EZG 600-mg/day (31%) and 900-mg/day
(17%) treatment groups were numerically higher compared with
those in the placebo group (0%). Seizure reduction appeared to be great-
er in the RTG/EZG 600-mg/day (−33.90%) treatment group compared
with that in the placebo (−22.21%) group, whereas the RTG/EZG
900-mg/day (−22.46%) treatment group was comparable with the
placebo group.
Efﬁcacy results were similar to previous RTG/EZG studies, which
included primarily Caucasian subjects. In 2007, for example, Porter et al.
reported the results of a 16-weekdouble-blind trial to evaluate adjunctive
RTG/EZG 600, 900, and 1200 mg/day in patients with partial-onset sei-
zures [4]. Median percent change in monthly total partial-onset seizure
frequency from baseline was−23% for RTG/EZG 600 mg/day,−29% for
RTG/EZG 900 mg/day, and −35% for RTG/EZG 1200 mg/day versus
−13% for placebo (p b 0.001 for overall difference across all treatment
arms). Responder rates were 23% for RTG/EZG 600 mg/day, 32% for
RTG/EZG 900 mg/day (p = 0.021), and 33% for RTG/EZG 1200 mg/day
(p = 0.016) versus 16% for placebo [4]. Similarly, in RESTORE 1, a multi-
center, randomized, double-blind, parallel-group study, the median per-
cent reduction in total partial-onset seizure frequency was 44.3% with
RTG/EZG 1200 mg/day versus 17.5% with placebo (p b 0.001) during
the 18-week double-blind period [6]. Responder rates (≥50% reduction
in total partial-onset seizure frequency from baseline) were 44.4% versus
17.8%, respectively (p b 0.001). In patients who entered the 12-week
open-label maintenance phase, median percent reductions in seizure fre-
quencywere 54.5% with RTG/EZG versus 18.9% with placebo (p b 0.001);
responder rateswere 55.5% versus 22.6%, respectively (p b 0.001) [6]. The
number of patients in the current study was too small to allowmeaning-
ful comparisons with these earlier studies. In the current study, although
greater seizure reduction was seen in the 600-mg/day group compared
with that in the placebo group, seizure reduction in the 900-mg/day
group was similar to that in the placebo group. The comparable efﬁcacy
in the 900-mg/day group may be due to the higher dropout rate during
titration; however, the premature termination of the study and the
small sample sizes do not provide sufﬁcient data to explore further.
Safety results were similar to those of previous studies in the clinical
development program, and no new safety concerns or ﬁndings were
identiﬁed. A greater proportion of patients in the RTG/EZG groups
than in the placebo group reported TEAEs. The proportion of patients
who discontinued the study drug owing to TEAEs increased with both
of the RTG/EZG doses. Consistent with the pivotal RTG/EZG studies, diz-
ziness and somnolence were the most common TEAEs in the RTG/EZG
groups, and there was an RTG/EZG dose relationship for TEAEs leading
to withdrawal.
As a potassium channel opener, RTG/EZG affects the function of the
smooth muscle of the bladder. The AE proﬁle of RTG/EZG therefore in-
cludes a risk of effects on the urinary system [9]. In clinical studies inves-
tigating the efﬁcacy and safety of RTG/EZG, an increased risk of urinary
retention was reported in patients receiving RTG/EZG compared with
those receiving placebo. In this study, 1 patient in the RTG/EZG 900-
mg/day group had a TEAE of urinary retention leading to withdrawal.
Treatment-related retinal pigmentation was not reported in any pa-
tients who underwent an eye examination. This is likely to have been
due to the brief exposure to treatment, as retinal pigmentation has
been observed generally after an extended course of treatment [10].
No patients discontinued owing to abnormal retinal pigmentation. In
June 2015, an FDA Drug Safety Communication stated that the potential
risks of vision loss due to pigment changes in the retina, as well as risks
of skin discoloration, could be adequately managed by following the
230 K.-S. Lim et al. / Epilepsy & Behavior 61 (2016) 224–230recommendations in the label update of October 2013 [11]. However,
the FDA considers that retigabine safety requires additional study, and,
at the time of writing, the manufacturer continues to monitor safety
with long-term observational studies.
This study was severely limited by the small sample size because of
early termination. Nevertheless, this is the largest study to date of Asian
patients treatedwithRTG/EZG in a double-blind, randomized controlled
trial design. The results suggest that the efﬁcacy and safety of adjunctive
RTG/EZG in Asian adults are broadly in line with those reported in pre-
vious studies and add to the limited data on RTG/EZG in this population.
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